Vertex Pharmaceuticals Announces Results Of First Interim Safety And Antiviral Analysis Of The PROVE 1 Clinical Trial For Hepatitis

Sun, 24 Dec 2006 02:00 PM EST

... Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from a planned interim safety analysis from PROVE 1, an ongoing Phase 2b clinical trial of the investigational hepatitis C virus (HCV) protease inhibitor telaprevir (VX-950): -- In the telaprevir dosing arms [click link for full article] ...